13 completed, 3 terminated, 2 unknown, 1 recruiting. 19 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 13, Terminated 3, Unknown 2, Recruiting 1 |
| Phase 2 | 6 | Completed 5, Unknown 1 |
Follow Bronchiectasis: new trials by email Literature Review of Bronchiectasis trials Research Report on Bronchiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients Placebo, CTX-187 - Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization | Phase 1 | Recruiting | Centauri Therapeutics Limited | 104 | 2026-06-16 | 2026-07-16 |
| Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance RCT1100 - Primary Ciliary Dyskinesia (PCD) | Phase 1 | Completed | ReCode Therapeutics | 14 | 2024-10-22 | 2026-04-30 |
| A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD RCT1100 - Primary Ciliary Dyskinesia | Phase 1 | Completed | ReCode Therapeutics | 7 | 2024-09-20 | 2025-10-08 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis CHF6333, CHF6333 Placebo - Bronchiectasis | Phase 1 / Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 108 | 2023-11-29 | 2026-10-26 |
| Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects RCT1100 - Primary Ciliary Dyskinesia | Phase 1 | Completed | ReCode Therapeutics | 9 | 2023-02-18 | 2025-04-29 |
| Autologous Transplantation of Bronchial Basal Cells for Treatment of Bronchiectasis Bronchial basal cells (BBCs), Bronchoscopic airway clearance treatment （B-ACT） - Bronchiectasis | Phase 1 / Phase 2 | Completed | Ruijin Hospital | 37 | 2020-06-21 | 2023-12-05 |
| Autologous Bronchial Basal Cells Transplantation for Treatment of Bronchiectasis Bronchial basal cells - Bronchiectasis | Phase 1 / Phase 2 | Unknown | Regend Therapeutics | 20 | 2016-03-01 | 2020-03-18 |
| Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis hMSCs - Bronchiectasis | Phase 1 | Completed | Marilyn Glassberg | 6 | 2016-02-04 | 2019-08-28 |
| Inhalation Flow Rate-study T-326 Inhaler - Bronchiectasis | Phase 1 | Completed | Bayer | 33 | 2015-11-23 | 2017-04-26 |
| Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients ALX-009, OSCN-, bLF - Cystic Fibrosis, Bronchiectasis | Phase 1 | Terminated | Alaxia SAS | 92 | 2015-11-01 | 2022-02-03 |
| Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Molgramostim, Placebo - Pulmonary Alveolar Proteinosis, Bronchiectasis | Phase 1 | Completed | Savara Inc. | 42 | 2015-05-01 | 2017-02-23 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects GSK2793660 solution, GSK2793660 capsule, Placebo solution - Bronchiectasis | Phase 1 | Terminated | GlaxoSmithKline | 33 | 2014-01-28 | 2018-09-13 |
| Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis Tobramycin - Bronchiectasis | Phase 1 / Phase 2 | Completed | University Medical Center Groningen | 8 | 2013-10-01 | 2014-12-16 |
| A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra) - Asthma, Bronchiectasis | Phase 1 | Completed | Ansun Biopharma, Inc. | 11 | 2010-07-01 | 2019-03-27 |
| Exercise Training in Patients With Non-cystic Fibrosis (CF) Bronchiectasis Exercise - Bronchiectasis | Phase 1 | Completed | Bayside Health | 39 | 2009-02-01 | 2014-03-11 |
| High Dose Inhaled Mannitol Study mannitol - Bronchiectasis | Phase 1 / Phase 2 | Completed | Syntara | 10 | 2009-01-01 | 2010-02-26 |
| A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device dry powder inhaled mannitol - Healthy, Bronchiectasis | Phase 1 / Phase 2 | Completed | Syntara | 15 | 2008-08-01 | 2009-09-18 |
| Study of the Effect of FLUTTER® VRP1 (PEP and Oscillating High Frequency). control group, Flutter group, PEP group - Bronchiectasis | Phase 1 | Terminated | University of Sao Paulo | 30 | 2007-07-01 | 2012-06-28 |
| Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation Pulmonary rehabilitation programme - Emphysema, Alveolitis, Fibrosing | Phase 1 | Unknown | Royal Brompton & Harefield NHS Foundation Trust | 60 | 2004-09-01 | 2005-09-07 |
Ciliary Motility Disorders (3) · Cystic Fibrosis (3) · Kartagener Syndrome (3) · Asthma (1) · Bacterial Infections (1) · Emphysema (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Pseudomonas Infections (1) · Pulmonary Alveolar Proteinosis (1) · Pulmonary Fibrosis (1) · Respiratory Distress Syndrome (1)
Bronchial Diseases (19) · Respiratory Tract Diseases (19) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Lung Diseases (4) · Abnormalities, Multiple (3) · Cardiovascular Abnormalities (3) · Cardiovascular Diseases (3) · Ciliopathies (3) · Congenital Abnormalities (3) · Dextrocardia (3) · Digestive System Diseases (3) · Heart Defects, Congenital (3) · Heart Diseases (3)
Colony-Stimulating Factors (1) · Control Groups (1) · Exercise (1) · GSK-2793660 (1) · Mannitol (1) · Population Groups (1) · Therapeutics (1) · Tobramycin (1) · hypothiocyanite ion (1) · molgramostim (1) · regramostim (1)
ReCode Therapeutics (3) · Syntara (2) · Alaxia SAS (1) · Ansun Biopharma, Inc. (1) · Bayer (1) · Bayside Health (1) · Centauri Therapeutics Limited (1) · Chiesi Farmaceutici S.p.A. (1) · GlaxoSmithKline (1) · Marilyn Glassberg (1) · Regend Therapeutics (1) · Royal Brompton & Harefield NHS Foundation Trust (1) · Ruijin Hospital (1) · Savara Inc. (1) · University Medical Center Groningen (1)
United Kingdom (6) · Australia (4) · United States (4) · China (2) · Germany (2) · Netherlands (2) · Brazil (1) · Denmark (1) · France (1) · New Zealand (1)
John Matthews, MBBS, MCRP, PhD (3) · Ada C. Gastaldi, doctor (1) · Annemarie L Lee, PhD (1) · Glassberg K Marilyn, MD (1) · Heymut Omran, MD (1) · Huib Kerstjens, MD, PhD (1) · Isabelle Durieu, Prof., MD (1) · James D. Chalmers (1) · Johnston Steward, MD (1) · Kenneth Olivier, MD, MPH, LCID, NIAID (1) · Kim G Nielsen, Dr Med Sci (1) · Michael Loebinger, MD (1)
PMID 11978924, PMID 1280928, PMID 20122281, PMID 24731015, PMID 26252343, PMID 26830468, PMID 28193704, PMID 28733314, PMID 28800383, PMID 30848695, PMID 34282853, PMID 39566467, PMID 40973220, PMID 9674466
2014 (1)